In all five primary AML samples, mebendazole treatment induced significant differentiation in the leukemia blasts as evidenced by increased expression of myeloid markers (CD11b, CD11c, and CD14) (Fig. 4a,c and Supplementary Fig. S4a). The gene discussed is ITGAM; the disease is leukemia.